GLP-1, GIP and Glucagon Receptor Mechanics

Keep the receptor targets distinct

The IUPHAR/BPS reference distinguishes the GLP-1, GIP and glucagon receptor targets. Its receptor interaction records (opens in a new tab) list the targets associated with individual ligands. A compound described as a dual or triple agonist should therefore be read as having a stated target profile, not as being interchangeable with other compounds in the same broad category.

Read the assay before comparing a number

Before comparing two reported activities, identify the receptor species, cell system, measured endpoint, reference ligand and calculation convention. A potency value concerns where a response occurs on an assay’s concentration scale; a maximum response concerns the extent of the observed response. A comparison without the underlying assay description is incomplete.

Keep results from different methods in separate fields. Similar-looking numbers should not be placed in one ranking merely because they share a unit.

How to read a multi-target paper

The original LY3437943 characterization paper (opens in a new tab) describes activity at the GIP, GLP-1 and glucagon receptors. It is an example of why target profiles are evaluated using more than one measurement.

When taking notes, separate the molecule’s identity from the assay results, the authors’ interpretation and any later clinical observations. Each belongs to a different part of the evidence record.

Avoid unsupported translation

A receptor result is not a treatment recommendation, a dosing conversion or proof that a different material has the same behavior. The next question is always what the experiment actually tested and whether that evidence supports the specific conclusion being considered.

This library provides terminology and reading context, not instructions for self-experimentation.